Table 2.

Sensitivity analysis based on the largest group of datasets (daily throughout and rifampicin throughout)

Criteria	Cut off	Datasets	Success	Failed	Relapsed	Defaulted
Study size	Small <166	9	0.91 (0.81–0.99)	0.03 (0.00–0.10)	0.02 (0.00–0.08)	0.03 (0.00–0.10)
	Big ≥166	10	0.90 (0.82–0.96)	0.04 (0.00–0.08)	0.01 (0.00–0.03)	0.05 (0.01–0.11)
Year of publication	Before 1999	8	0.98 (0.97–0.99)	0.01 (0.00–0.02)	0.01 (0.01–0.02)	0.00 (0.00–0.00)
	1999 and after	11	0.84 (0.76–0.91)	0.05 (0.01–0.10)	0.01 (0.00–0.03)	0.09 (0.04–0.15)
Country	African or African with other settings purely non-African	4	0.92 (0.84–0.98)	0.02 (0.00–0.07)	0.01 (0.00–0.05)	0.04 (0.00–0.10)
		15	0.89 (0.80–0.97)	0.04 (0.00–0.10)	0.01 (0.00–0.04)	0.05 (0.00–0.12)
Monitored therapy	Fully	6	0.90 (0.74–1.00)	0.04 (0.00–0.15)	0.02 (0.00–0.10)	0.04 (0.00–0.16)
	Partly/not at all/unspecified	13	0.90 (0.83–0.95)	0.04 (0.00–0.08)	0.01 (0.00–0.03)	0.05 (0.01–0.10)